Pulmonary Fibrosis News and Research

RSS

Fndings could lead to a treatment for idiopathic interstitial pneumonia

An incurable, deadly lung disorder, "idiopathic interstitial pneumonia" (IIP), whose causes were mysterious arises from a combination of a genetic predisposition and damage due to inhaled chemicals, notably from cigarette smoking, Duke University Medical Center researchers have found.

27 Sep 2005

Osteopontin protein found to be more common in patients with lung fibrosis

Idiopathic pulmonary fibrosis (IPF) is a scarring disease without a cure, irreparably damaging the ability of the tissue to transfer oxygen into the bloodstream.

6 Sep 2005

Two proteins for the diagnosis of lung diseases

Lung function pathology takes in some 200 diseases which have much radiological and pathological data in common, and which can greatly shorten the life of the patient, the last resort being a lung transplant.

1 Sep 2005

Female lung transplant recipients more likely to suffer from primary graft dysfunction

Female lung transplant recipients are significantly more likely to suffer from a type of injury to the transplanted lung called primary graft dysfunction than male lung transplant patients, according to a study presented at the American Thoracic Society International Conference.

25 May 2005

Promising results from study of Pirfenidone in idiopathic pulmonary fibrosis (IPF) patients

InterMune today announced that the American Journal of Respiratory and Critical Care Medicine (AJRCCM) published results from a double-blind, randomized, placebo-controlled Phase II trial evaluating pirfenidone for the treatment of patients with idiopathic pulmonary fibrosis (IPF).

2 May 2005

Idiopathic pulmonary fibrosis study points to survival as key endpoint in future actimmune studies

InterMune, Inc. today announced that CHEST, the journal of the American College of Chest Physicians, published an important analysis of variables that measure clinical outcomes in patients with idiopathic pulmonary fibrosis (IPF), a deadly and debilitating lung disease.

10 Jan 2005

Possible treatment for the fatal lung disease idiopathic pulmonary fibrosis

They found that the anti-cancer drug imatinib mesylate — commercially known as Gleevec and produced by Novartis Pharmaceuticals — can target a gene critical to controlling the disease process. Previously, there had been no treatment and patients usually did not survive beyond three years of diagnosis. Now the treatment is undergoing clinical trials at Mayo Clinic.

2 Nov 2004

New ways of looking at treatment for lung diseases such as pulmonary fibrosis

A research team at Yale University has found that blocking a kind of cell death called apoptosis in fibrotic diseases of the lung, also blocks the fibrosis, opening new ways of looking at treatment for lung diseases such as pulmonary fibrosis.

2 Sep 2004